United States & Eisai
11 shared events · Importance 3 · Last updated Aug 24, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
United States: Market where Leqembi Iqlik is now available; patients gain at-home treatment option.
Eisai: Partner responsible for development and commercialization; launched Leqembi Iqlik in the US, expanding its Alzheimer's franchise.
Aug 24, 2026 · 6 articles
International
United States: The United States' actions and statements regarding the conflict with Iran significantly impacted global crude oil prices and influenced market sentiment.
Eisai: Eisai's stock tumbled and declined, contributing to the negative performance of some pharmaceutical companies.
May 18, 2026 · 23 articles
Business
United States: Leqembi is approved in the US; subcutaneous formulation approved as Leqembi Iqlik.
Eisai: Eisai reported Leqembi sales of JPY 29.3 billion in Q2 2026, driving its revenue and partnership with Biogen.
Jul 29, 2026 · 6 articles
Business
United States: The United States is involved in geopolitical tensions with Iran and the Houthis, affecting global markets and oil prices.
Eisai: Eisai gained more than 3% on one day, reflecting gains.
Jul 24, 2026 · 37 articles
Business
United States: The U.S. was involved in geopolitical tensions with Iran, impacting global markets.
Eisai: Eisai declined almost 4%, underperforming the market.
Apr 21, 2022 · 26 articles
Business
United States: The United States is one of the countries where Leqembi is already approved; the India launch does not directly affect its market.
Eisai: Eisai is the primary actor, launching Leqembi in India, which could drive revenue growth and strengthen its position in the Alzheimer's treatment market.
Aug 03, 2026 · 6 articles
Business
United States: The United States market is where the newly approved Eribulin Mesylate Injection will be sold, impacting healthcare access and affordability for patients in the country.
Eisai: Eisai's Eribulin Injection is the reference listed drug for the newly approved generic Eribulin Mesylate Injection, indicating potential competition and market share impact for Eisai.
Jun 03, 2026 · 8 articles
Business
United States: The United States is the target market for Grey Matters Health Inc.'s expansion of neuroimaging clinics, addressing a growing demand for Alzheimer's detection and treatment within the country.
Eisai: Eisai, in collaboration with Biogen, developed Leqembi, one of the FDA-approved monoclonal antibody treatments for Alzheimer's Disease, which requires a positive beta-amyloid brain scan.
Jul 06, 2026 · 6 articles
Tech
Eisai: Eisai co-produces lecanemab (Leqembi), an anti-amyloid drug whose effectiveness was disputed by the Cochrane review, potentially leading to financial repercussions.
Apr 16, 2026 · 6 articles
Business
Eisai: Eisai, as the primary developer and commercializer of Lecanemab, presented the sales simulation, indicating strong future revenue growth for the company. This positively impacts its financial projections and market position.
May 25, 2026 · 7 articles
100
Eisai launched United StatesLeqembi Iqlik US launch
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States and Eisai interact across events, view sentiment trends, and discover connected entities.
Open Dashboard